RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw)SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, ...
In this video, Halle C. F. Moore, MD, discusses the EMBER-3 study update evaluating imlunestrant for women with hormone receptor-positive, HER2-negative breast cancer, presented at San Antonio Breast ...
Eli Lilly’s orforglipron pill helps maintain weight loss after Zepbound or Wegovy injections, with FDA review underway. Learn ...
Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...
Eli Lilly has shown patients maintained most of their weight loss after switching from injectable GLP-1s to its oral drug ...
Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could ...
Partnerships with giants like Eli Lilly and Thermo Fisher Scientific put biotech in the spotlight again, though founders still struggle to find investments in their hometown.
Eli Lilly & Co. reported positive topline results from a trial of its oral weight-management drug orforglipron.
Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results